Therapeutic antibodies for the treatment of pancreatic cancer. (Q55483367)

12 July 2018

1 reference

13 December 2019

Therapeutic antibodies for the treatment of pancreatic cancer. (English)

1 reference

12 July 2018

1 reference

27 September 2019

1 reference

13 December 2019

1

1 reference

12 July 2018

Daniel Baty

series ordinal

3

1 reference

12 July 2018

author name string

Brigitte Kerfelec

series ordinal

2

1 reference

12 July 2018

language of work or name

English

0 references

publication date

15 June 2010

7 references

12 July 2018

The Scientific World Journal

21 March 2019

24 March 2019

3 April 2019

27 September 2019

27 November 2019

13 December 2019

7 references

12 July 2018

21 March 2019

24 March 2019

3 April 2019

27 September 2019

27 November 2019

13 December 2019

10

1 reference

12 July 2018

page(s)

1107-1120

1 reference

12 July 2018

Creative Commons Attribution 3.0 Unported

copyright license

6 references

21 March 2019

24 March 2019

3 April 2019

27 September 2019

27 November 2019

on focus list of Wikimedia project

13 December 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.

1 reference

12 December 2020

Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4

1 reference

12 December 2020

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types

1 reference

12 December 2020

Identification of pancreatic cancer stem cells

1 reference

12 December 2020

Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy

1 reference

12 December 2020

Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study

1 reference

12 December 2020

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

1 reference

12 December 2020

Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)

1 reference

12 December 2020

Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays

1 reference

12 December 2020

Extracellular N-domain alone can mediate specific heterophilic adhesion between members of the carcinoembryonic antigen family, CEACAM6 and CEACAM8

1 reference

12 December 2020

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

1 reference

12 December 2020

Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution

1 reference

12 December 2020

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis

1 reference

12 December 2020

Early detection of pancreatic cancer: why, who, and how to screen

1 reference

12 December 2020

Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network

1 reference

12 December 2020

Bispecific antibodies for cancer therapy

1 reference

12 December 2020

Monoclonal antibody 16D10 to the COOH-terminal domain of the feto-acinar pancreatic protein targets pancreatic neoplastic tissues

1 reference

12 December 2020

Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays

1 reference

12 December 2020

Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis

1 reference

12 December 2020

Cancer statistics, 2009

1 reference

12 December 2020

Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen).

1 reference

12 December 2020

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers

1 reference

12 December 2020

Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts

1 reference

12 December 2020

High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas.

1 reference

12 December 2020

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

1 reference

12 December 2020

Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas

1 reference

12 December 2020

Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).

1 reference

12 December 2020

Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.

1 reference

12 December 2020

Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression.

1 reference

12 December 2020

Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma

1 reference

12 December 2020

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

1 reference

12 December 2020

PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.

1 reference

12 December 2020

Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.

1 reference

12 December 2020

Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent

1 reference

12 December 2020

Human carcinoembryonic antigen functions as a general inhibitor of anoikis

1 reference

12 December 2020

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

1 reference

12 December 2020

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.

1 reference

12 December 2020

Monoclonal antibody 16D10 to the C-terminal domain of the feto-acinar pancreatic protein binds to membrane of human pancreatic tumoral SOJ-6 cells and inhibits the growth of tumor xenografts

1 reference

12 December 2020

Transcriptional anti-angiogenesis therapy of human pancreatic cancer

1 reference

12 December 2020

Nuclear signalling by tumour-associated antigen EpCAM

1 reference

12 December 2020

A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma

1 reference

12 December 2020

Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution

1 reference

12 December 2020

Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target.

1 reference

12 December 2020

Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.

1 reference

12 December 2020

Metastatic pancreatic cancer 2008: is the glass less empty?

1 reference

12 December 2020

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

1 reference

12 December 2020

AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells

1 reference

12 December 2020

Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer.

1 reference

12 December 2020

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

1 reference

12 December 2020

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

1 reference

12 December 2020

Therapeutic antibodies: successes, limitations and hopes for the future

1 reference

12 December 2020

Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer

1 reference

12 December 2020

Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma

1 reference

12 December 2020

Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray

1 reference

12 December 2020

Stem cells, cancer, and cancer stem cells

1 reference

12 December 2020

EpCAM (CD326) finding its role in cancer

1 reference

12 December 2020

On the abundance of EpCAM on cancer stem cells

1 reference

12 December 2020

Accomplishments in 2008 in the treatment of metastatic pancreatic cancer.

1 reference

12 December 2020

Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma.

1 reference

12 December 2020

Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9

1 reference

12 December 2020

Mesothelin targeted cancer immunotherapy

1 reference

12 December 2020

Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu

1 reference

12 December 2020

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

12 December 2020

Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis

1 reference

12 December 2020

Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.

1 reference

12 December 2020

MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

1 reference

12 December 2020

A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer

1 reference

12 December 2020

Mesothelin: a new target for immunotherapy

1 reference

12 December 2020

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

1 reference

12 December 2020

Cancer-associated stromal fibroblasts promote pancreatic tumor progression

1 reference

12 December 2020

Catumaxomab: clinical development and future directions

1 reference

12 December 2020

Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer

1 reference

12 December 2020

Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer

1 reference

12 December 2020

Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.

1 reference

12 December 2020

Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts

1 reference

12 December 2020

Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.

1 reference

12 December 2020

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

1 reference

12 December 2020

Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer

1 reference

12 December 2020

IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor

1 reference

12 December 2020

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

1 reference

12 December 2020

Identifiers

DOI

10.1100/TSW.2010.103

1 reference

12 July 2018

release_kqbweje7wbgwnh4kudqtdhu344

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kqbweje7wbgwnh4kudqtdhu344

24 November 2022

mapped directly with Wikidata item

PMC publication ID

2925140

1 reference

12 July 2018

PubMed publication ID

20563534

1 reference

12 July 2018